GlassScriptPhysician profile
Jay S Balachandran
NPI 1396786273
$1,616.84
in general payments reported to CMS, 2019-2025
19 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.59 · 2020: $52.15 · 2022: $248 · 2023: $513 · 2024: $611 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,060 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,060.42 |
| Education | $188.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $311.10 | 2022-2025 | Wakix |
| Inspire Medical Systems, INC. | $300.03 | 2022-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $121.07 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $114.16 | 2023-2025 | Breztri, Fasenra |
| Baxter Healthcare | $111.55 | 2022-2024 | Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System |
| Insmed, INC. | $109.89 | 2023-2024 | Arikayce |
| Glaxosmithkline, LLC. | $87.09 | 2020-2024 | Nucala |
| Amgen INC. | $83.05 | 2024-2025 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $64.99 | 2023 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.29 | 2023-2024 | Stiolto Respimat, Spiriva Respimat |
| Avadel Cns Pharmaceuticals, LLC | $55.25 | 2023-2024 | Lumryz |
| Electromed, INC. | $45.51 | 2019-2024 | Smartvest |
| 3b Medical, INC. | $32.04 | 2024 | Luna |
| Genzyme Corporation | $26.95 | 2023 | |
| Itamar Medical INC | $26.74 | 2023-2025 | Watchpatone |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fisher & Paykel Healthcare INC | $24.99 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.40 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.80 | 2023 | Quviviq |
| United Therapeutics Corporation | $12.94 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Balachandran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.